Topic: precision medicine
Versant Ventures is unveiling Black Diamond Therapeutics, a biotech developing cancer treatments for an “undrugged and unexplored” group of oncogenes.
Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to $5.5 million.
We caught up with Tony Johnson, CEO at Goldfinch Bio, and discussed why investment and development in kidney disease has lagged.
Revolution Medicines is acquiring Warp Drive Bio, planning to combine the two companies’ drug discovery efforts and precision cancer therapy programs.
Mayo Clinic and OmniTier have shown that de novo whole genome sequencing can be done without the need for “supercomputing-level resources."
IBM and the VA extended their precision oncology partnership in applying Watson technology to the treatment of veterans with late-stage cancer.
Precision Therapeutics and Helomics have agreed to cement their close ties, aiming to share AI, diagnostics and CRO offerings.
The deal will further Roche’s precision medicine plans while allowing Foundation to retain autonomy and continue to work with other biopharmas.
Raising the cash sets Strata up to file for approval of a tumor molecular profiling assay while building out its platform.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.